» Articles » PMID: 29034266

Bladder Pain in an LL-37 Interstitial Cystitis and Painful Bladder Syndrome Model

Overview
Specialty Urology
Date 2017 Oct 17
PMID 29034266
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Our goal was to evaluate the pain response in an LL-37 induced murine model for interstitial cystitis/painful bladder syndrome (IC/PBS). In particular, we sought to characterize the dose dependence, time-course, and relationship of LL-37 induced bladder inflammation and pain. The IC/PBS model was induced in C57Bl/6 mice by instilling 50 μL of LL-37, an immunomodulatory human cathelicidin (anti-microbial peptide), in the bladder for 1 hr. Pain responses were measured using von Frey filaments (0.04 gm to 4.0 gm) before and after LL-37 instillation. Inflammation was evaluated using tissue myeloperoxidase (MPO) assay, gross inspection, and microscopic histologic examination. The dose response experiment demonstrated a graded pain response, with higher concentrations of LL-37 challenge yielding higher pain responses across all stimuli tested. Statistical significance was seen when comparing 1.0 gm von Frey filament results at 320 μM (68 ± 8% response) vs. 0 μM (38 ± 6% response). Interestingly, pain responses did not attenuate across time but increased significantly after 5 (p=0.0012) and 7 days (p=0.0096). Comparison with MPO data suggested that pain responses could be independent of inflammation. We demonstrated within our LL-37 induced IC/PBS model pain occurs in a dose-dependent fashion, pain responses persist beyond the initial point of insult, and our dose response and time course experiments demonstrated that pain was independent of inflammation.

Citing Articles

Positive correlational shift between crevicular antimicrobial peptide LL-37, pain and periodontal status following non-surgical periodontal therapy. A pilot study.

Madruga D, Garcia M, Martino L, Hassan H, Elayat G, Ghali L BMC Oral Health. 2023; 23(1):335.

PMID: 37246231 PMC: 10226254. DOI: 10.1186/s12903-023-03023-w.


Broaden Horizons: The Advancement of Interstitial Cystitis/Bladder Pain Syndrome.

Li J, Yi X, Ai J Int J Mol Sci. 2022; 23(23).

PMID: 36498919 PMC: 9736130. DOI: 10.3390/ijms232314594.


Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome.

Jensen M, Jia W, Schults A, Isaacson K, Steinhauff D, Green B Biomaterials. 2019; 217:119293.

PMID: 31276948 PMC: 6638575. DOI: 10.1016/j.biomaterials.2019.119293.


IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis model.

Jensen M, Jia W, Schults A, Ye X, Prestwich G, Oottamasathien S Cytokine. 2018; 110:420-427.

PMID: 29784508 PMC: 6103803. DOI: 10.1016/j.cyto.2018.05.012.

References
1.
Yoshimura N, Oguchi T, Yokoyama H, Funahashi Y, Yoshikawa S, Sugino Y . Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis. Int J Urol. 2014; 21 Suppl 1:18-25. PMC: 4089034. DOI: 10.1111/iju.12308. View

2.
Rudick C, Schaeffer A, Klumpp D . Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis. BMC Urol. 2009; 9:16. PMC: 2781023. DOI: 10.1186/1471-2490-9-16. View

3.
Carrico D, Sherer K, Peters K . The relationship of interstitial cystitis/painful bladder syndrome to vulvodynia. Urol Nurs. 2009; 29(4):233-8. View

4.
Rossberger J, Fall M, Jonsson O, Peeker R . Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. Urology. 2007; 70(4):638-42. DOI: 10.1016/j.urology.2007.05.028. View

5.
Theoharides T, Kempuraj D, Sant G . Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001; 57(6 Suppl 1):47-55. DOI: 10.1016/s0090-4295(01)01129-3. View